Medication of XNW5004, a EZH2 inhibitor in Evopoint, was completed in the first subject in Phase I clinical trial on August 3, 2021

XNW5004, developed by Evopoint, is an epigenetic EZH2 inhibitor, and was given to the first subject in Phase I clinical trial on August 3, 2021. The Principle Investigator (PI) of this clinical trial is the Hospital of Hematology, Chinese Academy of Medical Sciences.

EZH2 mutations are common in hematological malignancies, prostate cancer, breast cancer, ovarian cancer, small cell lung cancer, bladder cancer, liver cancer, etc. It has a significant association with the degree of malignancy and poor prognosis of tumors, and also correlates closely with the effect of tumor immunotherapy. Evopoint will continue to make every effort to promote the Phase I clinical trial of XNW5004 and strive to accelerate product launch for the benefit of numerous sufferers.